Quest Diagnostics has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for a self-collection kit for Covid-19.
The kit enables individuals to self-collect a nasal specimen at home by swabbing the front part of the nostril. It can also be used in healthcare settings when determined to be appropriate by a clinician.
The test is also available for children below 18-years-old, which must be used only under adult supervision.
Specimens are shipped overnight through FedEx at room temperature to Quest Diagnostics to be tested for Covid-19.
The company will use its SARS-CoV-2 RT-PCR test, which received EUA in March to analyse these samples.
Quest Diagnostics chairman, CEO and presidentSteve Rusckowski said: “Covid-19 molecular diagnostic testing has been constrained partly by limited supplies of swabs and trained healthcare professionals to do the specimen collection.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“The self-collection kit enables an individual to self-collect at home and the process is far less invasive and uncomfortable than many traditional methods.”
The company noted that it has already tested specimens using a similar collection method in real-world settings in the drive-thru and other Covid-19 testing sites in the US.
The self-collection test kits will be available to healthcare providers, states and organisations for return-to-work testing programmes.
Quest Diagnostics plans to have approximately a half-million kits available by the end of next month and aims to scale up the production on an ongoing basis.
Quest Diagnostics senior vice-president and chief medical officer Jay Wohlgemuth said: “We plan to use this device with a range of populations, from state-run programmes and employers to healthcare providers and individuals.
“Our scientists at our advanced diagnostics laboratory in San Juan Capistrano, California developed the technology, which has been validated in real-world studies.”
Last month, the company partnered with Centene to expand real-time reverse transcription-polymerase chain reaction (rRT-PCR) Covid-19 testing across the US.